Why Is Telomir Pharmaceuticals Stock Trading Higher On Tuesday?
Why Is Telomir Pharmaceuticals Stock Trading Higher On Tuesday?
These effects were also accompanied by increased survival rates in treated subjects.On Tuesday, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) revealed preclinical results confirming the efficacy of its licensed molecule Telomir-1 in reversing several key parameters of Type 2 diabetes mellitus.
贝莱德周二透露，Telomir制药公司（纳斯达克股票代码：TELO）公布了一项临床前研究结果，证实其授权分子Telomir-1在扭转2型糖尿病的数个关键参数上的功效。
The study demonstrated significant reductions in fasting plasma glucose levels to basal levels, improved oral glucose homeostasis, and reversed insulin resistance to near pre-diabetic levels.
该研究显示，空腹血糖水平显著降低至基线水平，口服葡萄糖稳态改善，胰岛素抵抗降至接近糖尿病前的水平。
These findings were supported by significantly improved Homeostatic Model Assessment of Insulin Resistance values, a standard measure used to assess insulin sensitivity and resistance.
这些发现得到了家ostasis Model Assessment of Insulin Resistance的显著改善，这是用于评估胰岛素敏感性和耐受性的标准指标。
These effects were also accompanied by increased survival rates in treated subjects.
这些效果还伴随着接受治疗对象的提高存活率。
The company adds that Telomir-1 directly addresses oxidative stress and beta-cell damage by normalizing iron metabolism.
公司补充说，Telomir-1直接解决氧化应激和β-细胞损伤，通过规范铁代谢来实现。
In collaboration with the India-based research organization Pentagrit, Telomir evaluated two forms of Telomir-1, administered orally at three doses, in zebrafish models.
与总部位于印度的研究机构Pentagrit合作，Telomir在斑马鱼模型中评估了两种形式的Telomir-1，口服三种剂量。
Recently, Telomir Pharmaceuticals' preclinical results showed that Telomir-1 demonstrates significant age-reversal effects. These effects include an extended healthy lifespan, improved mobility, and a measurable reversal of age-related decline.
最近，Telomir制药公司的临床前结果显示，Telomir-1展示出重大的年龄逆转效果。这些效果包括延长健康寿命、改善机动能力以及可量化逆转与年龄相关的衰退。
Telomir is advancing additional research, including:
Telomir正在推进额外的研究，包括：
- Progeria (causes rapid aging): Evaluating Telomir-1's effects on human progeria cell lines and progeria nematode models to investigate its impact on accelerated aging and telomere function and stability.
- Diabetic Mouse Models: Further validating Telomir-1's efficacy in a mammalian model of Type 2 diabetes.
- Alzheimer's Disease: Initiating studies to assess Telomir-1's potential in mitigating cognitive decline and neurodegeneration.
- Osteoarthritis and Inflammatory Diseases: Evaluating Telomir-1's role in managing joint health and other age-related inflammatory conditions.
- Cancer Models: Exploring Telomir-1's application in combating age-related oncological conditions.
- Progeria（导致快速老化）：评估Telomir-1对人类快老细胞系和快老线虫模型的影响，以探究其对加速衰老、端粒功能和稳定性的影响。
- 糖尿病小鼠模型：进一步验证Telomir-1在2型糖尿病哺乳动物模型中的有效性。
- 阿尔茨海默病：启动研究以评估Telomir-1在减轻认知衰退和神经退行方面的潜力。
- 骨关节炎和炎症性疾病：评估Telomir-1在管理关节健康和其他与年龄相关的炎症性状况中的作用。
- 癌症模型：探索Telomir-1在对抗与年龄相关的肿瘤条件中的应用。
Price Action: TELO stock is up 15.4% at $4.905 at last check Tuesday.
价格走势：TELO股票在上周二最新数据显示涨幅为15.4%，报4.905美元。
- BlackRock Makes $12 Billion Power Move – Agrees To Acquire HPS To Bolster Private Credit Offerings
- 贝莱德（BlackRock）120亿美元重磅动作 - 同意收购HPS以增强私人信贷业务。
Image via Shutterstock.
图片由shutterstock提供。
译文内容由第三方软件翻译。